Kilitch Drugs India Share Price
Sector: Biotechnology & Drugs
416.40 -14.00 (-3.25%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
412.65
Today’s High
429.90
52 Week Low
271.30
52 Week High
500.05
419.10 -3.55 (-0.84%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
415.25
Today’s High
430.00
52 Week Low
299.95
52 Week High
499.00
Key Metrics
- Market Cap (In Cr) 670.29
- Beta 0.71
- Div. Yield (%) 0
- P/B 3.35
- TTM P/E 22.15
- Sector P/E 26.03
- D/E 0
- Open Price 429.9
- Prev Close 430.4
Kilitch Drugs India Analysis
Price Analysis
-
1 Week-8.54%
-
3 Months35.82%
-
6 Month26.2%
-
YTD29.37%
-
1 Year29.45%
Risk Meter
- 48% Low risk
- 48% Moderate risk
- 48% Balanced Risk
- 48% High risk
- 48% Extreme risk
Kilitch Drugs India News
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy
1 min read . 30 Apr 2025Multibagger MSME stock hits upper circuit on two days in a row after Q4 results
2 min read . 02 Jun 2023Kilitch Drugs India Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 198.32
- Selling/ General/ Admin Expenses Total
- 11.32
- Depreciation/ Amortization
- 3.11
- Other Operating Expenses Total
- 31
- Total Operating Expense
- 169.96
- Operating Income
- 28.36
- Net Income Before Taxes
- 34.47
- Net Income
- 26.7
- Diluted Normalized EPS
- 16.6
- Period
- 2025
- Total Assets
- 312.78
- Total Liabilities
- 110.45
- Total Equity
- 202.33
- Tangible Book Valueper Share Common Eq
- 114.06
- Period
- 2025
- Cashfrom Operating Activities
- 17.54
- Cashfrom Investing Activities
- -39.95
- Cashfrom Financing Activities
- 13.24
- Net Changein Cash
- -9.16
- Period
- 2024
- Total Revenue
- 154.37
- Selling/ General/ Admin Expenses Total
- 30.34
- Depreciation/ Amortization
- 3.35
- Other Operating Expenses Total
- 2.87
- Total Operating Expense
- 133.41
- Operating Income
- 20.97
- Net Income Before Taxes
- 19.35
- Net Income
- 14.6
- Diluted Normalized EPS
- 9.7
- Period
- 2024
- Total Assets
- 240.06
- Total Liabilities
- 63.77
- Total Equity
- 176.29
- Tangible Book Valueper Share Common Eq
- 97.29
- Period
- 2024
- Cashfrom Operating Activities
- -0.15
- Cashfrom Investing Activities
- -9.54
- Cashfrom Financing Activities
- 8.81
- Net Changein Cash
- -0.88
- Period
- 2023
- Total Revenue
- 139.6
- Selling/ General/ Admin Expenses Total
- 30.32
- Depreciation/ Amortization
- 3.55
- Other Operating Expenses Total
- 1
- Total Operating Expense
- 125.58
- Operating Income
- 14.02
- Net Income Before Taxes
- 12.01
- Net Income
- 10.45
- Diluted Normalized EPS
- 7.25
- Period
- 2023
- Total Assets
- 219.52
- Total Liabilities
- 67.92
- Total Equity
- 151.6
- Tangible Book Valueper Share Common Eq
- 84.14
- Period
- 2023
- Cashfrom Operating Activities
- 2.59
- Cashfrom Investing Activities
- 7.92
- Cashfrom Financing Activities
- -0.72
- Net Changein Cash
- 9.78
- Period
- 2022
- Total Revenue
- 114.23
- Selling/ General/ Admin Expenses Total
- 22.57
- Depreciation/ Amortization
- 2.47
- Other Operating Expenses Total
- 5.54
- Total Operating Expense
- 105.61
- Operating Income
- 8.62
- Net Income Before Taxes
- 9.61
- Net Income
- 7.37
- Diluted Normalized EPS
- 5.27
- Period
- 2022
- Total Assets
- 209.85
- Total Liabilities
- 70.76
- Total Equity
- 139.09
- Tangible Book Valueper Share Common Eq
- 75.59
- Period
- 2022
- Cashfrom Operating Activities
- 5.78
- Cashfrom Investing Activities
- -15.25
- Cashfrom Financing Activities
- 7.03
- Net Changein Cash
- -2.44
- Period
- 2021
- Total Revenue
- 68.52
- Selling/ General/ Admin Expenses Total
- 18.6
- Depreciation/ Amortization
- 1.99
- Other Operating Expenses Total
- 0.47
- Total Operating Expense
- 65.29
- Operating Income
- 3.23
- Net Income Before Taxes
- 5.12
- Net Income
- 3.67
- Diluted Normalized EPS
- 2.37
- Period
- 2021
- Total Assets
- 203.18
- Total Liabilities
- 76.05
- Total Equity
- 127.13
- Tangible Book Valueper Share Common Eq
- 67.81
- Period
- 2021
- Cashfrom Operating Activities
- 45.66
- Cashfrom Investing Activities
- -37.57
- Cashfrom Financing Activities
- 1.61
- Net Changein Cash
- 9.7
- Period
- 2020
- Total Revenue
- 53.32
- Selling/ General/ Admin Expenses Total
- 16.55
- Depreciation/ Amortization
- 2
- Other Operating Expenses Total
- 0.55
- Total Operating Expense
- 55.03
- Operating Income
- -1.71
- Net Income Before Taxes
- 1.61
- Net Income
- 0.84
- Diluted Normalized EPS
- 0.55
- Period
- 2020
- Total Assets
- 142.83
- Total Liabilities
- 24.58
- Total Equity
- 118.25
- Tangible Book Valueper Share Common Eq
- 61.85
- Period
- 2020
- Cashfrom Operating Activities
- 3.75
- Cashfrom Investing Activities
- -10.45
- Cashfrom Financing Activities
- 1.57
- Net Changein Cash
- -5.14
- Period
- 2019
- Total Revenue
- 82.49
- Selling/ General/ Admin Expenses Total
- 16.93
- Depreciation/ Amortization
- 2.05
- Other Operating Expenses Total
- 0.41
- Total Operating Expense
- 76.54
- Operating Income
- 5.95
- Net Income Before Taxes
- 8.59
- Net Income
- 3.83
- Diluted Normalized EPS
- 2.61
- Period
- 2019
- Total Assets
- 143.66
- Total Liabilities
- 22.6
- Total Equity
- 121.06
- Tangible Book Valueper Share Common Eq
- 63.46
- Period
- 2019
- Cashfrom Operating Activities
- 0.29
- Cashfrom Investing Activities
- -13.98
- Cashfrom Financing Activities
- 16.86
- Net Changein Cash
- 3.17
- Period
- 2025-03-31
- Total Revenue
- 61.23
- Selling/ General/ Admin Expenses Total
- 2.88
- Depreciation/ Amortization
- 0.85
- Other Operating Expenses Total
- 8.62
- Total Operating Expense
- 47.48
- Operating Income
- 13.75
- Net Income Before Taxes
- 13.84
- Net Income
- 10.4
- Diluted Normalized EPS
- 6.47
- Period
- 2025-03-31
- Total Assets
- 312.78
- Total Liabilities
- 110.45
- Total Equity
- 202.33
- Tangible Book Valueper Share Common Eq
- 114.06
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 17.54
- Cashfrom Investing Activities
- -39.95
- Cashfrom Financing Activities
- 13.24
- Net Changein Cash
- -9.16
- Period
- 2024-12-31
- Total Revenue
- 56.17
- Selling/ General/ Admin Expenses Total
- 3.14
- Depreciation/ Amortization
- 0.81
- Other Operating Expenses Total
- 7.36
- Total Operating Expense
- 48.24
- Operating Income
- 7.93
- Net Income Before Taxes
- 8.25
- Net Income
- 5.96
- Diluted Normalized EPS
- 3.71
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 47.47
- Selling/ General/ Admin Expenses Total
- 2.59
- Depreciation/ Amortization
- 0.61
- Other Operating Expenses Total
- 8.59
- Total Operating Expense
- 41.99
- Operating Income
- 5.49
- Net Income Before Taxes
- 10.35
- Net Income
- 8.62
- Diluted Normalized EPS
- 5.36
- Period
- 2024-09-30
- Total Assets
- 259.43
- Total Liabilities
- 70.1
- Total Equity
- 189.32
- Tangible Book Valueper Share Common Eq
- 105.68
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 2.32
- Cashfrom Investing Activities
- -15.69
- Cashfrom Financing Activities
- -0.26
- Net Changein Cash
- -13.64
- Period
- 2024-06-30
- Total Revenue
- 33.45
- Selling/ General/ Admin Expenses Total
- 2.71
- Depreciation/ Amortization
- 0.85
- Other Operating Expenses Total
- 6.81
- Total Operating Expense
- 32.64
- Operating Income
- 0.81
- Net Income Before Taxes
- 1.65
- Net Income
- 1.34
- Diluted Normalized EPS
- 0.83
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 44.82
- Selling/ General/ Admin Expenses Total
- 2.37
- Depreciation/ Amortization
- 0.93
- Other Operating Expenses Total
- 5
- Total Operating Expense
- 38.67
- Operating Income
- 6.15
- Net Income Before Taxes
- 5.3
- Net Income
- 3.59
- Diluted Normalized EPS
- 2.24
- Period
- 2024-03-31
- Total Assets
- 240.06
- Total Liabilities
- 63.77
- Total Equity
- 176.29
- Tangible Book Valueper Share Common Eq
- 97.29
- Period
- 2024-03-31
- Cashfrom Operating Activities
- -0.15
- Cashfrom Investing Activities
- -9.54
- Cashfrom Financing Activities
- 8.81
- Net Changein Cash
- -0.88
- Period
- 2023-12-31
- Total Revenue
- 31.79
- Selling/ General/ Admin Expenses Total
- 2.51
- Depreciation/ Amortization
- 0.81
- Other Operating Expenses Total
- 7.06
- Total Operating Expense
- 30.33
- Operating Income
- 1.47
- Net Income Before Taxes
- 2.82
- Net Income
- 2.91
- Diluted Normalized EPS
- 1.85
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Kilitch Drugs India Technical
Moving Average
SMA
- 5 Day453.46
- 10 Day459.93
- 20 Day431.24
- 50 Day385.12
- 100 Day354.02
- 300 Day343
Kilitch Drugs India Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Shree Ganesh Remedies
- 622
- 8.9
- 1.45
- 950.05
- 600
- 799.57
- Sudarshan Pharma Industries
- 31
- 0.5
- 1.64
- 53.5
- 5.82
- 746.04
- Kilitch Drugs India
- 416.4
- -14
- -3.25
- 500.05
- 271.3
- 670.29
- Aayush Wellness
- 142.4
- 2.75
- 1.97
- 139.65
- 16.58
- 693.08
- Ngl Fine-chem
- 1074
- -19.35
- -1.77
- 2774.4
- 962.7
- 663.52
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Shree Ganesh Remedies
- 34.14
- 5.42
- 21.94
- 20.52
- Sudarshan Pharma Industries
- 40.89
- 5.58
- -
- -
- Kilitch Drugs India
- 25.46
- 3.36
- 8.32
- 8.41
- Aayush Wellness
- 202.39
- 82.08
- 6.88
- 0.77
- Ngl Fine-chem
- 32.03
- 2.4
- 18.34
- 12.15
Kilitch Drugs India Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 19-May-25
- Audited Results
- 11-Feb-25
- Quarterly Results
- 12-Nov-24
- Quarterly Results
- 08-Aug-24
- Quarterly Results
- 27-May-24
- Quarterly Results
- 08-Feb-24
- Quarterly Results
- 09-Nov-23
- Quarterly Results
- 11-Aug-23
- Quarterly Results
- 22-Jul-23
- Others
- 29-May-23
- Audited Results
- Meeting Date
- Announced on
- Purpose
- 27-Sept-24
- 06-Sept-24
- AGM
- 29-Sept-23
- 14-Aug-23
- AGM
- 11-Apr-23
- 16-Mar-23
- EGM



